Studies were conducted to examine the functional role of the nucleotide-binding domains of MRP in drug resistance and drug transport in isolated membrane vesicles. In vivo studies were conducted by preparing stable transfectants of HeLa cells with wild-type MRP cDNA or MRP cDNAs which had been mutated at certain nucleotide binding domains (NBD). Stable transfectants producing equivalent amounts of the MRP encoded protein P190 were used in this study. The results demonstrated that deletions in the C-motif of NBD1 or the A-motif of NBD2 have a pronounced effect in reducing resistance levels to chemotherapeutic agents. Certain single-site mutations in lysines in these same motifs also reduce IC 50 values. It has also been observed that mutation of the MRP NBDs results in an increase in drug accumulation and a reduction in drug efflux. Additional studies have been carried out in which recombinant baculovirus containing either wild-type MRP or MRP containing mutated NBDs was prepared and used to infect SF21 insect cells. Using this system we have analyzed the effects of these mutations on in vitro transport of leukotriene C 4 (LTC 4 ) 17 β-estradiol 17 (β-D-glucuronide)(E 2 17βG) and daunomycin in membrane vesicles prepared from baculovirus infected cells. The results demonstrate that deletions and site-specific mutations in MRP NBDs greatly reduce the ATP dependent transport of all three substrates. The results of these studies conducted both in vivo and in vitro demonstrate that the NBDs of MRP function in a cooperative manner and are critical for the transport activity of the MRP encoded protein P190. These studies also identify specific lysines in NBD1 and NBD2 which are important for optimal MRP activity.
Introduction
Experimental cell lines isolated for multidrug resistance frequently overexpress either of the genes MDR1 (Endicott and Ling, 1989) or the Multidrug Resistant Protein (MRP) gene (Cole et al., 1992) . Transfection experiments indicate that both MDR1 (Gros et al., 1986) and MRP (Grant et al., 1994; Zaman et al., 1994; Kruh et al., 1994) can confer drug resistance to sensitive cells. The product of MDR1 is a phosphoglycoprotein which migrates in SDS gels as a 170-180 kd protein (Endicott and Ling, 1989) . P-glycoprotein which has been extensively studied contains 2 nucleotide-binding domains (NBD) defined by the Walker A and Walker B sequences (Walker et al., 1982) . Previous studies have demonstrated that both NBDs of P-glycoprotein are needed for functional activity (Azzaria, et al., 1989) . P-glycoprotein contains ATPase activity (Hamada and Tourao 1988; Ambudkar et al., 1992) but only one NBD seems to be necessary for functional activity of this enzyme (Shimabuka et al., 1992) . The MRP encoded protein P190 (Krishnamachry and Center, 1993) is also a phosphoglycoprotein (Krishnamachary et al., 1994 : Ma et al., 1993 Almquist et al., 1995) which is located predominantly in the plasma membranes and endoplasmic reticulum of resistant cells (Krishnamachary et al., 1994 , Barrand et al., 1995 . The protein is highly phosphorylated with phosphate groups contained in at least 9 trypic peptides (Ma et al., 1993) . All phosphate groups are present at serine residues (Ma et al., 1993) . It has also been observed that certain protein kinase inhibitors such as chelerythrine are capable of reducing P190 phosphorylation and reversing drug resistance (Ma et al., 1993) . Further studies are needed however to clearly determine if phosphorylation plays some role in the function of P190. The MRP encoded protein contains 2 putative NBDs as determined by sequence analysis (Cole et al., 1992) . Further evidence for the presence of NBDs in P190 has been previously obtained by labeling the protein with the photoactive agent 8-azido (α32P) ATP (McGrath et al., 1989) . Although P-glycoprotein and P190 have only 15% sequence homology both function in an energy requiring drug efflux system which reduces the intracellular accumulation of drug (Endicott and Ling, 1989; Versantvoort et al., 1992) . Both proteins can mediate resistance against a broad spectrum of structurally unrelated drugs and P-glycoprotein appears capable of binding and transporting drug (Endicott and Ling, 1989) , whereas studies conducted thus far have been unable to demonstrate that P190 is capable of binding free drug (McGrath et al., 1989) . P190 is however capable of binding to and transporting the glutathione-S-conjugate LTC 4 in isolated membrane vesicles Leier et al., 1994; Muller et al., 1994) . The protein is also capable of transporting in vitro oxidized glutathione (Leier et al., 1996) cholestatic glucuronidated steroids and chemotherapeutic agents such as vincristine and daunomycin (Saptarshi et al., 1996) . Vincristine transport in vitro seems to be greatly enhanced by the presence of glutathione , whereas daunomycin transport can occur in the absence of glutathione (Saptarshi et al., 1996) . A major question concerning MRP function is whether in vivo drug is transported in the form of an anionic conjugate. Two reviews have recently appeared which describe in detail the biology of the MRP system Lautier et al., 1996) .
In Vivo Analysis of the Involvement of MRP NBDs in Multidrug Resistance
Although extensive studies have been carried out to characterize MRP mediated multidrug resistance (Lautier et al., 1996; there have been no previous reports concerned with analyzing functional domains of the MRP encoded protein P190 through the use of site directed mutagenesis. To initiate studies of this type we have mutagenized MRP cDNA at putative nucleotide-binding domains (NBDs) and have used mutated and wild-type DNA in expression vectors to produce stable transfectants in HeLa cells. The effect of these mutations on levels of drug resistance, drug accumulation and drug efflux were examined in detail. Mutagenesis of NBDs resulted in deletion mutants in the NBD1, C-motif (dN 1 ) and the NBD2, A-motif (dN 2 ) (Figure 1) . A double deletion mutant dN 1 dN 2 was also constructed (Figure 1 ). In addition single site mutations were introduced into lysine of NBD1, C-motif converting this amino acid to methionine (sN 1 ), and, also lysine in the NBD2 A-motif (sN 2 ) (Figure 1 ). A double mutant containing both single-site mutations was also prepared (sN 1 sN 2 ). The presence of the various mutations in the MRP cDNA was verified by sequence analysis (Sanger et al., 1977) . Membranes were prepared from Hela cells transfected with the wild-type and mutated MRP cDNAs and the levels of P190 were determined by Western blot analysis. The results of this study clearly demonstrated that about equal levels of wildtype and mutated P190 were contained in membranes of transfected cells. The electrophoretic mobility of the mutated proteins in SDS gels demonstrated the presence of full length proteins with a molecular mass of about 190 kd. The stable transfectants were thereafter analyzed for resistance levels against adriamycin, vincristine and VP-16. It was observed in agreement with other studies (Grant et al., 1994; Zaman et al., 1994; Kruh et al., 1994 ) that wild-type MRP could confer drug resistance to drug sensitive HeLa cells (Table I) . For reasons that are not known wild-type transfectants showed a higher level of resistance to vincristine as compared to adriamycin and VP-16. Detailed studies were thereafter carried out to determine the effect of the various NBD mutations on MRP mediated cell resistance. It was observed that all NBD mutants had a pronounced effect in reducing resistance to all 3 chemotherapeutic agents tested (Table I) . Reduction in resistance was found to be somewhat greater with the deletion mutants as compared to the single-site mutants. It is of interest to note that deletion of either the NBD1 C-motif or the NBD2 A-motif results in a major reduction in resistance thus indicating that both NBDs are needed for optimal MRP resistance and that one NBD cannot compensate for another. At the present time it is not known however if the 2 MRP NBDs have similar or different functions The deletions (shaded sequences) are represented by dN 1 , dN 2 and the double deletion dN 1 N 2 . Also K (lysine) indicated by the asterisk was mutated to M (methionine) in both the C-motif and A-motifs resulting in sN 1 , sN 2 and the doubel single-site mutant sN 1 N 2 . The materials and methods used for construction of MRP-NBD mutants, cytotoxicity assays, drugs accumulation and efflux were as previously described (Zhu et al., 1997) . in MRP drug transport. It was also observed that either of the single site mutants in lysines of the NBD1 Cmotif or NBD2 A-motif produced a major reduction in IC 50 values with either adriamycin, vincristine or VP-16 (Table I) . Thus the single lysines at position 773 (C-motif) or 1333 (A-motif) play a major role in the functional activity of MRP. Previous studies indicate that the lysine present in the Walker A motif interacts with the phosphate group of ATP (Walker et al., 1982) . The function of the lysine in the C-motif is not known but it may be important in maintaining the structural integrity of this linker region (Walker et al., 1982) .
Effect of MRP NBD Mutations on Drug Accumulation and Efflux
Previous studies have demonstrated that most experimental isolates overexpressing MRP exhibit a reduction in the accumulation of drug (Marsh et al., 1986; Coley et al., 1991; Versantvoort, et al., 1992) . In MRP transfectants reduced accumulation of drug which requires ATP is also observed Cole et al., 1994) . It is also indicated that reduced drug accumulation is related to an energy requiring efflux system . In the P-glycoprotein system it would be indicated that the NBDs play a role in the P-glycoprotein ATPase which releases energy for efflux of drug against a concentration gradient. At the present time the P190 protein has not been purified and there is still no evidence that this protein contains an ATPase. Thus to gain insight into the function of the MRP NBDs studies were conducted to examine drug accumulation and efflux in transfectants containing P190 mutated at nucleotide-binding domains (Figures 2 and 3) . Thus in these experiments HeLa cells transfected with wild-type or mutated MRP were incubated in the presence of [ 3 H] daunomycin and the accumulation of drug over various time periods was determined (Figure 2) . The results clearly demonstrate that wild-type transfected cells exhibit a major reduction in drug accumulation compared to cells transfected with the empty vector. Cells containing MRP mutated at NBDs exhibit a major increase in the accumulation of drug. The relative levels of drug accumulation occurring in cells containing either the dN 1 or dN 2 mutations are about the same thus demonstrating once again that deletion of either the NBD1 C-motif or NBD2 A-motif results in a cell with a drug sensitive phenotype. Thus a single intact NBD site does not seem capable of functioning to reduce drug accumulation. Similarly the single site mutants sN 1 or sN 2 also render the NBD sites inactive resulting in a major increase in drug accumulation (Figure 2 ). Thus the single lysines mutated in this study seem to play a critical role in the functional activity of the MRP NBDs. Additional studies have been carried out to examine drug efflux in HeLa cell transfectants containing either wild-type or mutated MRP cDNA. The results of this study reveal that the rate of drug efflux in wild-type transfected cells after a 90 min incubation period was about 2-fold greater than that found for the various deletion mutants (Figure 3) . Efflux in cells transfected with these mutants was equivalent to that occurring in cells transfected with the empty vector thus indicating that either the dN 1 or dN 2 mutation essentially abolishes MRP mediated drug efflux. The rate of drug efflux was also reduced with either of the single-site mutants sN 1 or sN 2 . The rate was somewhat further reduced in the transfectant containing the double single-site mutations sN 1 N 2 .
Taken together the results of these studies provide definitive evidence that drug resistance in the MRP system is related to an energy dependent efflux which reduces cellular accumulation of drug. The mechanism by which the MRP encoded protein P190 carries out the function remains to be determined.
In Vitro Analysis of MRP Mediated Substrate Transport: Effect of MRP NBD Mutations on Transport in Isolated Membrane Vesicles
Previous studies have shown that membrane vesicles prepared from cells overexpressing MRP are capable of the ATP dependent transport of a number of compounds including the leukotriene glutathione conjugate LTC 4 Leier et al., 1994; Muller et al., 1994) and also certain chemotherapeutic agents such as daunomycin and vincristine. (Saptarshi et al., 1996 . In recent studies we have developed a recombinant baculovirus which contains a full length MRP cDNA (Sun et al., 1996) . Infection of SF 21 insect cells with this virus results in the synthesis of a deglycosylated form of the MRP protein. In SDS gels the protein has a molecular mass of about 170 kd. The P170 protein is phosphorylated and associated with cell membranes. The deglycosylated protein appears to be functional in the in vitro system since membrane vesicles containing P170 can transport LTC 4 in an ATP dependent reaction . Transport of MRP substrates in membrane vesicles prepared from wild-type or NBD mutated MRP cDNA contained in recombinant baculovirus. Baculovirus was also prepared with transfer vector which did not contain MRP cDNA (designated EV). Transport studies (Sun et al., 1996) were carried out with membrane vesicles prepared from baculovirus infected SF21 cells. The substrates used were [ 3 H] LTC 4 (panels A and B); [ 3 H]E 2 17βG (panels C and D) and [ 3 H] daunomycin (panels E and F). (Sun et al., 1996) . In view of this and in an effort to extend these findings we have prepared recombinant baculovirus containing wild-type MRP or MRP containing the NBD mutations described in Figure 1 . Thus in these experiments insect cells were infected with recombinant virus and the effect of mutated NBDs on MRP mediated transport was examined (Figure 4) . In these experiments all transport studies were conducted with membrane vesicles containing equivalent levels of MRP-P170 as determined by Western blot analysis. The MRP specific antibody 6KQ (Krishnamachary and Center 1994) was used in these studies. It was observed from these experiments that the effect of the NBD mutations on transport in vitro is quite similar to that found in the in vivo system using stable transfectants of Hela cells. Thus it was observed that transport of LTC 4 , E 2 17β-D-glucuronide and daunomycin was reduced at least 75% with either deletion mutant dN 1 or dN 2 as compared to transport activity obtained with vesicles prepared from cells infected with recombinant baculovirus containing wild-type MRP (Figure 4) . Similar results were obtained with the single site lysine mutants sN 1 or sN 2 . Thus in the presence of either mutant in vitro transport with the three substrates tested was greatly reduced compared to transport obtained in the presence of wild-type MRP. The finding that single-site mutants reduce MRP mediated transport suggests that the transport alterations observed are probably not due to topological changes of the P170 protein in the membrane. The results point to the finding that lysine-773 of the NBD1 C-motif or lysine-1333 of the NBD2 A-motif play critical roles in the nucleotide binding domains of MRP.
